More clinical trial sites should be included: CDSCO Panel tells Akum Pharma over Letrozole tablet

Published On 2023-07-11 12:30 GMT   |   Update On 2023-07-11 12:30 GMT
Advertisement

New Delhi: Noting more clinical trial sites should be included to have geographically distributed sites across India, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has granted approval to the drug major Akums Pharmaceutical to conduct the clinical trial of Letrozole Tablets 5mg.

This came after the firm presented the proposal for amendment of clinical trial protocol version no 2.1.

Advertisement

Letrozole is used to stimulate egg development and ovulation in female patients undergoing fertility treatment. Letrozole is an oral fertility medication. It can be used to induce ovulation in women who don’t ovulate or to produce multiple eggs in women who already ovulate on their own.

Letrozole is also used for treating breast cancer. It can also help prevent breast cancer from coming back. It is mainly prescribed for women who have been through menopause and have a type of cancer called "hormone-dependent" breast cancer.

Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have previously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer.

At the recent SEC meeting for reproductive and urology held on 21st June 2023, the expert panel reviewed the proposal presented by the drug major Akums Pharmaceuticals for the protocol amendment of clinical trial protocol version no 2.1. for Letrozole Tablets 5mg.

After detailed deliberation, the committee recommended the grant of permission to conduct the clinical trial as per the protocol presented.

In continuation, the expert panel also recommended that more clinical trial sites should be included to have geographically distributed sites across India.

Also Read:Sun Pharma Gets CDSCO Panel Nod to Manufacture, Market Gabapentin for neuropathic pain

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News